Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1978 Mar;54(629):190–195. doi: 10.1136/pgmj.54.629.190

The place of the hyperlipidaemias

June K Lloyd, Richard J West
PMCID: PMC2425186  PMID: 206883

Abstract

Of the primary hyperlipidaemias, familial hypercholesterolaemia (hyerbetalipoproteinaemia, type II) is always expressed in childhood and carries a high risk for the early development of coronary heart disease. The diagnosis can be established with a high degree of certainty by estimating the serum cholesterol concentration in selected children in whom the genetic risk is known to be great, e.g. if a parent or other first-degree relative is known to have the disease, or if a parent has had an attack of ischaemic heart disease at a young age. Screening of the general population in order to detect this disorder is not advocated. Treatment by either diet or drugs will lower serum cholesterol but long-term compliance is poor and the effect of treatment on the atherosclerotic process has not been evaluated. Follow-up studies must be maintained.

Familial hypertriglyceridaemic states are rarely fully expressed during childhood, and screening for them at this age is not practicable. Control of co-existent obesity and dietary treatment are usually successful in lowering serum lipids but long-term results have not yet been evaluated.

In a childhood population, single estimations of serum cholesterol or triglyceride should be interpreted with caution. Percentile rank correlations for serum cholesterol are of the order of 0·61 and for triglyceride of 0·31. Prediction of adult values cannot therefore be assured in childhood and the place of hyperlipidaemia in the childhood population as a risk factor for coronary heart disease in adult life is not established. Thus population screening of serum lipids in children cannot be justified. Evidence that a change in the diet of children which would be expected to lower serum lipids will also delay the development of atherosclerosis in general and coronary heart disease in particular is lacking. Nevertheless the dietary changes which have been recommended for adults can safely be followed by children, and changes in eating habits are perhaps more likely to succeed if promoted on a family basis rather than for individual sections of the population.

Full text

PDF
190

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Carlson L. A., Böttiger L. E. Ischaemic heart-disease in relation to fasting values of plasma triglycerides and cholesterol. Stockholm prospective study. Lancet. 1972 Apr 22;1(7756):865–868. doi: 10.1016/s0140-6736(72)90738-6. [DOI] [PubMed] [Google Scholar]
  2. Darmady J. M., Fosbrooke A. S., Lloyd J. K. Prospective study of serum cholesterol levels during first year of life. Br Med J. 1972 Jun 17;2(5815):685–688. doi: 10.1136/bmj.2.5815.685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Dietary and drug treatment of primary hyperlipoproteinemia. Ann Intern Med. 1972 Aug;77(2):267–294. doi: 10.7326/0003-4819-77-2-267. [DOI] [PubMed] [Google Scholar]
  4. Drash A. Atherosclerosis, cholesterol, and the pediatrician. J Pediatr. 1972 Apr;80(4):693–696. doi: 10.1016/s0022-3476(72)80086-6. [DOI] [PubMed] [Google Scholar]
  5. Farah J. R., Kwiterovich P. O., Jr, Neill C. A. Dose-effect relation of cholestryamine in children and young adults with familial hypercholesterolaemia. Lancet. 1977 Jan 8;1(8002):59–63. doi: 10.1016/s0140-6736(77)91078-9. [DOI] [PubMed] [Google Scholar]
  6. Glueck C. J., Fallat R. W., Mellies M., Tsang R. C. Pediatric familial type II hyperlipoproteinemia: therapy with diet and colestipol resin. Pediatrics. 1976 Jan;57(1):68–74. [PubMed] [Google Scholar]
  7. Glueck C. J., Fallat R. W., Tsang R. Hypercholesterolemia and hypertriglyceridemia in children. A pediatric approach to primary atherosclerosis prevention. Am J Dis Child. 1974 Oct;128(4):569–577. doi: 10.1001/archpedi.1974.02110290139025. [DOI] [PubMed] [Google Scholar]
  8. Glueck C. J., Fallat R., Buncher C. R., Tsang R., Steiner P. Familial combined hyperlipoproteinemia: studies in 91 adults and 95 children from 33 kindreds. Metabolism. 1973 Nov;23(2):1403–1428. doi: 10.1016/0026-0495(73)90256-4. [DOI] [PubMed] [Google Scholar]
  9. Glueck C. J., Tsang R. C., Fallat R. W., Mellies M. Therapy of familial hypercholesterolemia in childhood: diet and cholestyramine resin for 24 to 36 months. Pediatrics. 1977 Mar;59(3):433–441. [PubMed] [Google Scholar]
  10. Glueck C. J., Tsang R., Fallat R., Buncher C. R., Evans G., Steiner P. Familial hypertriglyceridemia: studies in 130 children and 45 siblings of 36 index cases. Metabolism. 1973 Oct;22(10):1287–1309. doi: 10.1016/0026-0495(73)90274-6. [DOI] [PubMed] [Google Scholar]
  11. Joossens J. V., Brems-Heyns E., Claes J. H., Graffar M., Kornitzer M., Pannier R., Van Houte O., Vuylsteek K., Carlier J., De Backer G. The pattern of food and mortality in Belgium. Lancet. 1977 May 21;1(8021):1069–1072. [PubMed] [Google Scholar]
  12. Kwiterovich P. O., Jr, Levy R. I., Fredrickson D. S. Neonatal diagnosis of familial type-II hyperlipoproteinaemia. Lancet. 1973 Jan 20;1(7795):118–121. doi: 10.1016/s0140-6736(73)90194-3. [DOI] [PubMed] [Google Scholar]
  13. Larsen R., Glueck C. J., Tsang R. Special diet for familial type II hyperlipoproteinemia. Am J Dis Child. 1974 Jul;128(1):67–72. doi: 10.1001/archpedi.1974.02110260069012. [DOI] [PubMed] [Google Scholar]
  14. Leonard J. V., Fosbrooke A. S., Lloyd J. K., Wolff O. H. Screening for familial hyper-beta-lipoproteinaemia in children in hospital. Arch Dis Child. 1976 Nov;51(11):842–847. doi: 10.1136/adc.51.11.842. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Leonard J. V., Whitelaw A. G., Wolff O. H., Lloyd J. K., Slack J. Diagnosing familial hypercholesterolaemia in childhood by measuring serum cholesterol. Br Med J. 1977 Jun 18;1(6076):1566–1568. doi: 10.1136/bmj.1.6076.1566. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Morganroth J., Levy R. I., Fredrickson D. S. The biochemical, clinical, and genetic features of type III hyperlipoproteinemia. Ann Intern Med. 1975 Feb;82(2):158–174. doi: 10.7326/0003-4819-82-2-158. [DOI] [PubMed] [Google Scholar]
  17. Patterson D., Slack J. Lipid abnormalities in male and female survivors of myocardial infarction and their first-degree relatives. Lancet. 1972 Feb 19;1(7747):393–399. doi: 10.1016/s0140-6736(72)90853-7. [DOI] [PubMed] [Google Scholar]
  18. Segall M. M., Fosbrooke A. S., Lloyd J. K., Wolff O. H. Treatment of familial hypercholesterolaemia in children. Lancet. 1970 Mar 28;1(7648):641–644. doi: 10.1016/s0140-6736(70)90884-6. [DOI] [PubMed] [Google Scholar]
  19. Slack J. Genetic differences in liability to atherosclerotic heart disease. J R Coll Physicians Lond. 1974 Jan;8(2):115–126. [PMC free article] [PubMed] [Google Scholar]
  20. Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet. 1969 Dec 27;2(7635):1380–1382. doi: 10.1016/s0140-6736(69)90930-1. [DOI] [PubMed] [Google Scholar]
  21. Stamler J., Epstein F. H. Coronary heart disease: risk factors as guides to preventive action. Prev Med. 1972 Mar;1(1):27–48. doi: 10.1016/0091-7435(72)90076-x. [DOI] [PubMed] [Google Scholar]
  22. Stanhope J. M., Sampson V. M. High-density-lipoprotein cholesterol and other serum lipids in a New Zealand biracial adolescent sample. The Wairoa College survey. Lancet. 1977 May 7;1(8019):968–970. doi: 10.1016/s0140-6736(77)92275-9. [DOI] [PubMed] [Google Scholar]
  23. West R. J., Lloyd J. K. The effect of cholestyramine on intestinal absorption. Gut. 1975 Feb;16(2):93–98. doi: 10.1136/gut.16.2.93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. West R. J., Lloyd J. K. Use of cholestyramine in treatment of children with familial hypercholesterolaemia. Arch Dis Child. 1973 May;48(5):370–374. doi: 10.1136/adc.48.5.370. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES